http://www.fpnotebook.com/
Pemoline
Aka: Pemoline, Cylert
- Indications
- Attention Deficit Hyperactivity Disorder (ADHD)
- Not recommended as first line agent
- Pharmacokinetics
- Onset: 2 hours
- Duration: 6 to 10 hours
- Steady state reached in 2 to 3 days
- Titrate dose every 3 to 4 weeks
- Dosing
- Range: 0.5 - 2.5 mg/kg/dose (Up to 112.5 mg/day)
- Start: 18.75 mg PO qAM
- Frequency: Once to twice daily
- Monitoring
- Alanine Aminotransferase (ALT)
- Obtain baseline
- Repeat testing every 2 weeks
- Symptom inquiry at every visit
- Anorexia
- Malaise
- Gastrointestinal symptoms
- Dark urine
- Precautions
- Informed consent from parents required prior to use
- Adverse Effects
- Hepatic failure of dysfunction
- Choreoathetoid movements
- Other adverse effects similar to Methylphenidate
- References
- (1996) Pediatrics 98:301-4
- Andesman (1999) Pediatr Clin North Am 46:945-63
- Bennett (1999) Pediatr Clin North Am 46:929-44
- Challman (2000) Mayo Clin Proc 75:711-21